Celebrex GI Safety, Warfarin Claims Over Vioxx Need Corrective Letter - FDA
Executive Summary
Pharmacia should issue a Celebrex "Dear Healthcare Provider Letter" to correct violative safety information disseminated about the COX-2 inhibitor during an audioconference series and in two professional sales pieces, a Feb. 1 FDA warning letter states.
You may also be interested in...
Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test
The Vioxx withdrawal will prompt renewed debate over DTC advertising
Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test
The Vioxx withdrawal will prompt renewed debate over DTC advertising
Merck Vioxx Warning Letter Could Be Incentive For Large Cardio Safety Study
Merck's Vioxx warning letter may serve as an additional incentive for the company to conduct a large cardiovascular safety study.